Phaseline

Targets › CD47

CD47 (Leukocyte surface antigen CD47): drug programs, companies and trials

8 programs from 7 companies in 28 trials: 15 Phase 1, 11 Phase 2, 2 Phase 3; Oncology, Hematology; next expected readout Dec 2026.

Adhesive protein that mediates cell-to-cell interactions. Acts as a receptor for thrombospondin THBS1 and as modulator of integrin signaling through the activation of heterotrimeric G proteins. (UniProt, Q08722)

Open in Phaseline: the race on CD47, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AkesoAK117
anti-CD47 antibody
CD47Phase 3Head and Neck Squamous Cell Carcinoma; Higher-risk Myelodysplastic Syndromes; Metastatic Triple-negative Breast Cancer; Resectable Gastric or Gastroesophageal Junction Adenocarcinoma …Dec 2026
Suzhou Suncadia BiopharmaceuticalsSHR-A1912
CD47 antagonist/signal regulatory protein alpha (SIRPα) blockade
CD47Phase 3Diffuse Large B-cell LymphomaMar 2027
ALX OncologyEvorpacept (ALX148)
Leukocyte surface antigen CD47 inhibitor
CD47Phase 2Gastric Cancer; Head and Neck Cancer; Breast Cancer, Metastatic; Ovarian Cancer …Dec 2027
FBD BiologicsHCB101
SIRPα-Fc fusion protein targeting CD47
SIRPA, CD47Phase 1Advanced Solid Tumor; Solid Cancer; CRC; HNSCCMay 2027
Ono PharmaceuticalMagrolimab (ONO-7913)
Leukocyte surface antigen CD47 inhibitor
CD47Phase 1Metastatic Pancreatic Cancer; Unresectable Colorectal CancerJun 2027
Phanes TherapeuticsPeluntamig (PT217)
Bispecific antibody against DLL3 and CD47
DLL3, CD47Phase 1Small Cell Lung Cancer (SCLC)Dec 2027
Phanes TherapeuticsSpevatamig (PT886)
Bispecific antibody targeting Claudin 18.2 and CD47
CLDN18, CD47Phase 1Gastric or Gastroesophageal Junction AdenocarcinomaDec 2027
PfizerMaplirpacept
CD47-SIRP alpha-directed immune checkpoint inhibitor
CD47Phase 1Multiple MyelomaFeb 2028

Conditions

Head and Neck Cancer (2) Head and Neck Squamous Cell Carcinoma (1) Higher-risk Myelodysplastic Syndromes (1) Metastatic Triple-negative Breast Cancer (1) Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (1) Extensive-stage Small Cell Lung Cancer (ES-SCLC) (1) Metastatic Colorectal Cancer (1) Acute Myeloid Leukemia (1) Myelodysplastic Syndrome (1) Advanced Malignant Tumors (1) Classic Hodgkin Lymphoma (1) Gastric Cancer (1)

Modalities

mixed (7), small molecule (1)

Companies

Phanes Therapeutics (2) Akeso (1) ALX Oncology (1) Pfizer (1) Suzhou Suncadia Biopharmaceuticals (1) Ono Pharmaceutical (1) FBD Biologics (1)

Related targets

SIRPA (1) DLL3 (1) CLDN18 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.